for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Hutchison China MediTech Limited

HCM.L

Latest Trade

376.50GBp

Change

12.50(+3.43%)

Volume

9,773

Today's Range

360.50

 - 

376.50

52 Week Range

260.50

 - 

552.00

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
364.00
Open
363.50
Volume
9,773
3M AVG Volume
1.40
Today's High
376.50
Today's Low
360.50
52 Week High
552.00
52 Week Low
260.50
Shares Out (MIL)
666.79
Market Cap (MIL)
2,417.18
Forward P/E
-25.66
Dividend (Yield %)
--

Next Event

Hutchison China MediTech Ltd Annual Shareholders Meeting

Latest Developments

More

Hutchison China MediTech, Innovent Expand Collaboration On Sintilimab & Surufatinib

Hutchison China MediTech Initiates Phase I/IB Trial of HMPL-523 in Lymphoma

Hutchison China Meditech Says CK Hutchison To Sell 1.3% Stake At $17.65 Per ADR

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Hutchison China MediTech Limited

Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures markets and distributes prescription drugs and consumer health products in China.

Industry

Biotechnology & Drugs

Contact Info

22Nd Floor Hutchison House

10 Harcourt Road

+852.null.21213888

http://www.chi-med.com/

Executive Leadership

Simon To

Executive Chairman of the Board

Christian Hogg

Chief Executive Officer, Executive Director

Chig Fung Cheng

Chief Financial Officer, Executive Director

Weiguo Su

Chief Scientific Officer, Executive Director

Edith Shih

Company Secretary, Non-Executive Director

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.2K

2017

0.2K

2018

0.2K

2019(E)

0.2K
EPS (USD)

2016

0.020

2017

-0.043

2018

-0.113

2019(E)

-0.184
Price To Earnings (TTM)
--
Price To Sales (TTM)
14.62
Price To Book (MRQ)
9.00
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
2.08
LT Debt To Equity (MRQ)
1.07
Return on Investment (TTM)
-20.47
Return on Equity (TTM)
-15.77

Latest News

Latest News

Biotech group Chi-Med plans Hong Kong listing of up to $500 million: sources

Biotech company Hutchison China MediTech, known as Chi-Med, has filed for a Hong Kong listing, which four sources close to the matter said could raise up to $500 million.

Boost for 'made in China' medicine as Chi-Med wins key approval

Hutchison China MediTech has won Chinese approval for a closely watched new cancer drug in a significant boost for "made in China" medicine.

Boost for "made in China" medicine as Chi-Med wins key approval

Hutchison China MediTech has won Chinese approval for a closely watched new cancer drug in a significant boost for "made in China" medicine.

China cancer specialist Chi-Med plans $262 mln share offering

China-based cancer and immunology drug specialist Hutchison China MediTech, or Chi-Med, said it aimed to offer $262 million of American Depositary Shares, subject to market conditions, to help fund development of its pipeline.

BRIEF-Astrazeneca says co and Chi-med's Savolitinib shows encouraging clinical activity

* Astrazeneca and Chi-med’s Savolitinib shows encouraging clinical activity in 2nd-line EGFR mutation-positive lung cancer with met-amplification

Chi-Med steps closer to Chinese pharma first with drug filing

(This story corrects to remove reference to Lilly in paragraph 4.)

BRIEF-Hutchison China Meditech Ltd says may offer to sell in one or more offerings ADS representing ordinary shares

* Hutchison China Meditech Ltd - files to say may offer to sell in one or more offerings American Depositary Shares representing ordinary shares - SEC filing Source text for Eikon: (http://bit.ly/2oB4NcB) Further company coverage:

BRIEF-Hutchison China Meditech FY group revenue up 21 pct

* FY net income attributable to Chi-Med of $11.7 million versus $8.0 million year ago Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up